德國Diarect AG
在過去的20年里,DIARECT AG公司的專家致力于自身免疫分析的大量創新研究與開發:
1、基于重組甲狀腺過氧化物酶(TPO)的最早的甲狀腺過氧化物酶抗體的測試系統;
2、使用了幾種重組蛋白的最早的抗核抗體(ANA) /多肽抗體(ENA )的分布和篩選分析;
3、最初的重組蛋白有增殖細胞核抗原(PCNA), 蘇胺酰-tRNA合成酶(PL-7), 丙胺酰-tRNA合成酶(PL-12) , 全長的 Mi-2蛋白, Ku (p70/p80) 等.
我們的承諾是進一步擴大產品系列,在未來的幾年來我們將繼續致力于開發新的自身抗原。
在免疫分析產品方面多年的經驗告訴我們,產品的性能取決于高品質的原料結合精益求精的研發。同等重要的還有關鍵原料質量的可重復性,從而使產品后繼生產過程中的偏差降到最低。我們的專長是大批量生產以及保持各批次產品之間的一致性。
DIARECT AG的公司目標是通過提供優質產品來改善分析的質量水平從而增強分析性能。這個理念促使我們援助世界各地的病人和臨床免疫學家,與研究人員的科學合作,以及我們自己進行的學術參與,都促使著我們在這個方向上努力。
Over the last two decades our experts have been involved in a number of innovative autoimmune assay developments:
First thyroid peroxidase antibody test system, based on recombinant TPO
First ANA/ENA profile and screening assay, utilizing several recombinant proteins
Introduction recombinant PCNA, PL-7, PL-12, full length Mi-2?, Ku (p70/p80) etc.
Since we are committed to further expand our product panel, we will strive to continue the development of new autoantigens in the years to come.
Manufacturing Experience
Years of experience in immunoassay production have taught us that test performance is the result of sophisticated assay development in combination with high-quality components. Equally important is the reproducible quality of these key components in order to minimize deviation in the subsequent manufacturing process. Large lot sizes as well as lot-to-lot consistency is our expertise.
Committed to Clinical Science
We at DIARECT AG aim to enhance assay performance by providing superior components for an improved assay quality level. This concept drives us to support patients and clinical immunologists worldwide. Scientific collaborations with researchers as well as our own ongoing academic involvement facilitate our efforts in this direction.